![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Thadani Udho
Publisher: Adis International
ISSN: 1175-3277
Source: American Journal of Cardiovascular Drugs, Vol.9, Iss.3, 2009-05, pp. : 211-212
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
High-dose lisinopril feasible in high-risk patients with HF
Inpharma, Vol. 1, Iss. 1271, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
ATP III update targets high-risk patients, statins market to benefit?
Inpharma, Vol. 1, Iss. 1447, 2004-01 ,pp. :